DTIL
Price
$7.17
Change
-$0.07 (-0.97%)
Updated
Sep 11 closing price
Capitalization
197.9M
59 days until earnings call
Intraday BUY SELL Signals
INVA
Price
$20.66
Change
+$0.04 (+0.19%)
Updated
Sep 11 closing price
Capitalization
1.49B
60 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DTIL vs INVA

DTIL vs INVA Comparison Chart in %
View a ticker or compare two or three
VS
DTIL vs. INVA commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DTIL is a StrongBuy and INVA is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INVA($1.49B) has a higher market cap than DTIL($198M). INVA has higher P/E ratio than DTIL: INVA (4.79) vs DTIL (4.53). DTIL YTD gains are higher at: 72.356 vs. INVA (3.352). INVA has higher annual earnings (EBITDA): 464M vs. DTIL (-49.7M). INVA has more cash in the bank: 579M vs. DTIL (87.5M). DTIL has less debt than INVA: DTIL (28.1M) vs INVA (270M). INVA has higher revenues than DTIL: INVA (440M) vs DTIL (45.1M).
DTILINVADTIL / INVA
Capitalization198M1.49B13%
EBITDA-49.7M464M-11%
Gain YTD72.3563.3522,159%
P/E Ratio4.534.7994%
Revenue45.1M440M10%
Total Cash87.5M579M15%
Total Debt28.1M270M10%
FUNDAMENTALS RATINGS
DTIL vs INVA: Fundamental Ratings
DTIL
INVA
OUTLOOK RATING
1..100
6419
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
55
Fair valued
PROFIT vs RISK RATING
1..100
10071
SMR RATING
1..100
9928
PRICE GROWTH RATING
1..100
4158
P/E GROWTH RATING
1..100
9999
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INVA's Valuation (55) in the Pharmaceuticals Other industry is in the same range as DTIL (56) in the Biotechnology industry. This means that INVA’s stock grew similarly to DTIL’s over the last 12 months.

INVA's Profit vs Risk Rating (71) in the Pharmaceuticals Other industry is in the same range as DTIL (100) in the Biotechnology industry. This means that INVA’s stock grew similarly to DTIL’s over the last 12 months.

INVA's SMR Rating (28) in the Pharmaceuticals Other industry is significantly better than the same rating for DTIL (99) in the Biotechnology industry. This means that INVA’s stock grew significantly faster than DTIL’s over the last 12 months.

DTIL's Price Growth Rating (41) in the Biotechnology industry is in the same range as INVA (58) in the Pharmaceuticals Other industry. This means that DTIL’s stock grew similarly to INVA’s over the last 12 months.

DTIL's P/E Growth Rating (99) in the Biotechnology industry is in the same range as INVA (99) in the Pharmaceuticals Other industry. This means that DTIL’s stock grew similarly to INVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DTILINVA
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
66%
Momentum
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
62%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
66%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
61%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
58%
Advances
ODDS (%)
Bullish Trend 22 days ago
78%
Bullish Trend 10 days ago
64%
Declines
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 2 days ago
64%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
64%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
64%
COMPARISON
Comparison
Sep 12, 2026
Stock price -- (DTIL: $7.17 vs. INVA: $20.66)
Brand notoriety: DTIL and INVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DTIL: 61% vs. INVA: 75%
Market capitalization -- DTIL: $197.9M vs. INVA: $1.49B
DTIL [@Biotechnology] is valued at $197.9M. INVA’s [@Biotechnology] market capitalization is $1.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DTIL’s FA Score shows that 0 FA rating(s) are green while INVA’s FA Score has 1 green FA rating(s).

  • DTIL’s FA Score: 0 green, 5 red.
  • INVA’s FA Score: 1 green, 4 red.
According to our system of comparison, INVA is a better buy in the long-term than DTIL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DTIL’s TA Score shows that 3 TA indicator(s) are bullish while INVA’s TA Score has 3 bullish TA indicator(s).

  • DTIL’s TA Score: 3 bullish, 7 bearish.
  • INVA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, INVA is a better buy in the short-term than DTIL.

Price Growth

DTIL (@Biotechnology) experienced а -4.02% price change this week, while INVA (@Biotechnology) price change was -3.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

DTIL is expected to report earnings on Nov 10, 2026.

INVA is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
DTIL
Daily Signal:
Gain/Loss:
INVA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FMXSX9.04N/A
N/A
Federated Hermes Max-Cap Index Svc
MEQFX19.38N/A
N/A
AMG River Road Large Cap Value Select I
FITIX26.20N/A
N/A
Fidelity Advisor Mid Cap II M
CSCIX15.11N/A
N/A
Cohen & Steers Real Estate Securities C
MXETX14.54N/A
N/A
Empower Core Strategies US Eq Inv